Critical care and infectious disease specialist Innoviva Specialty Therapeutics Inc (IST), a subsidiary of Innoviva Inc (Nasdaq:INVA), revealed on Monday that it has secured exclusive US marketing rights to Zevtera (ceftobiprole) from Swiss biopharmaceutical R&D company Basilea Pharmaceutica Ltd (SIX:BSLN).
Zevtera is an advanced-generation cephalosporin antibiotic approved by the US Food and Drug Administration (FDA) for treating various bacterial infections, including MRSA.
Innoviva plans to commercialise Zevtera in the United States in mid-2025.
This acquisition strengthens Innoviva's product portfolio and expands its presence in the infectious disease market.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval